Nicotinic acetylcholine receptors as targets for antidepressants

Molecular Psychiatry

Volumn 7, Issue 6, 2002, Pages 525-535

  Shytle, R D ^a   Silver, A A ^a   Lukas, R J ^b   Newman, M B ^a   Sheehan, D V ^a   Sanberg, P R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Antidepressant; Cholinergic; Depression; Mechanism; Nicotinic

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR; CITALOPRAM; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MECAMYLAMINE; MONOAMINE; NEFAZODONE; NICOTINIC RECEPTOR; NISOXETINE; NOMIFENSINE; PAROXETINE; SERTRALINE; VENLAFAXINE; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT;

AFFECTIVE NEUROSIS; ARTICLE; CIRCADIAN RHYTHM; COMORBIDITY; DEPRESSION; DOPAMINERGIC SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIMBIC SYSTEM; MANIC DEPRESSIVE PSYCHOSIS; MONOAMINE METABOLISM; MONOAMINE RELEASE; NEUROTRANSMISSION; PRIORITY JOURNAL; RECEPTOR BLOCKING; BIOLOGICAL MODEL; BRAIN; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SYNTHESIS;

ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; DEPRESSIVE DISORDER; DRUG DESIGN; HUMAN; MODELS, NEUROLOGICAL; NICOTINE; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; HUMANS;

EID: 0036024247     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001035     Document Type: Article

References (139)

1. The catecholamine hypothesis of affective disorders: A review of supporting evidence
2. The biochemistry of affective disorders
3. Mechanism of action of antidepressant medications
4. Toward a better understanding of depression: New mechanistic considerations of antidepressant action provide a basis for development of delay-free drugs
5. 5-HT and 5-HIAA in cerebrospinal fluid in depression
6. Antidepressant effect of a tryptophan hydroxylase activation inhibitor, AGN 2979
7. Tianeptine, a selective enhancer of serotonin uptake in rat brain
8. Non-correlation of preclinical-clinical evaluation of a prosposed anti-depressant 4-phenylbicyclo(2, 2, 2)octan-1-amine hydrochloride monohydrate (EXP 561)
9. A molecular and cellular theory of depression
10. Neuronal plasticity and survival in mood disorders
11. Interaction of imipramine with the ionic channel of the acetylcholine receptor of motor endplate and electric organ
12. Inhibition of 22Na influx by tricyclic and tetracyclic antidepressants and binding of [3H]imipramine in bovine adrenal medullary cells
13. Tricyclic antidepressants block cholinergic nicotinic receptors and ATP secretion in bovine chromaffin cells
14. Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants
15. Differential inhibition of catecholamine secretion by amitriptyline through blockage of nicotinic receptors, sodium channels, and calcium channels in bovine adrenal chromaffin cells
16. Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine
17. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac)
18. Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices
19. Effects of fluoxetine on wild and mutant neuronal alpha 7 nicotinic receptors
20. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function
21. Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices
22. Nicotinic acetylcholine receptor antagonistic activity of the selective dopamine uptake blocker GBR-12909 in rat hippocampal slices
23. Bupropion is a nicotinic antagonist
24. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine
25. What is the nature of mecamylamine's antagonism of the central effects of nicotine?
26. Nicotine-mecamylamine treatment for smoking cessation: The role of pre- cessation therapy
27. A comparison of sustained-release bupropion and placebo for smoking cessation
28. The role of corticotropin releasing factor in depressive illness: A critical review
29. The neurobiology of depression
30. The stress-induced response of the septo-hippocampal cholinergic system. A vectorial outcome of psychoneuroendocrinological interactions
31. Cholinomimetic and anticholinergic drugs used to investigate and acetylcholine hypothesis of affective disorders and stress
32. A cholinergic-adrenergic hypothesis of mania and depression
33. Is cholinergic sensitivity a genetic marker for the affective disorders?
34. Acetylcholine and depression
35. Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and bipolar patients
36. Pharmacological challenge strategies: Implications for neurochemical mechanisms in affective disorders and treatment approaches
37. Effect of lithium on the physostigmine-induced behavioral syndrome and plasma cyclic GMP
38. Is cholinergic sensitivity a genetic marker for the affective disorders?
39. Brain choline in depression: In vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy
40. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy
41. Serotonergic and cholinergic interaction in the regulation of pituitary-adrenal function in rats
42. Sexual diergism in rat hypothalamic-pituitary-adrenal axis responses to cholinergic stimulation and antagonism
43. Stress modulation over the day in cigarette smokers
44. Smoking, smoking cessation, and major depression
45. Cigarette smoking
46. Depression and the dynamics of smoking. A national perspective
47. Cigarette smoking and major depression
48. Major depression following smoking cessation
49. Nicotine cessation, Mania, and depression
50. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression
51. Antidepressant effects of nicotine in an animal model of depression
52. Antidepressant-like effects of chronic nicotine on learned helplessness paradigm in rats
53. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression
54. Depressive characteristics of FSL rats: Involvement of central nicotinic receptors
55. Role of high affinity nicotinic receptors in learned helplessness behavior
56. Prospective social-psychological factors of adolescent smoking progression
57. Is smoking associated with depression and anxiety in teenagers?
58. Depression, anxiety and smoking initiation: A prospective study over 3 years
59. Depressive symptoms and cigarette smoking among teens
60. Smoking and panic attacks: An epidemiologic investigation
61. Cigarette smoking, major depression, and other psychiatric disorders among adolescents
62. Smoking and major depression. A causal analysis
63. Baseline-dependency of nicotine effects: A review
64. Overview of nicotinic receptors and their roles in the central nervous system
65. Neuronal nicotinic aceytlcholine receptors
66. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes
67. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits
68. Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions
69. Modulatory role of presynaptic nicotinic receptors in synaptic non-synaptic chemical communication in the central nervous system
70. Nicotinic receptors in the brain. Links between molecular biology and behavior
71. Regulation by nicotine of its own receptors
72. Sustained nicotine exposure differentially affects alpha 3 beta 2 and alpha 4 beta 2 neuronal nicotinic receptors expressed in Xenopus oocytes
73. Pharmacokinetic considerations in understanding nicotine dependence
74. Variations in desensitization of nicotinic acetylcholine receptors from hippocampus and midbrain dopamine areas
75. Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine
76. Effects of chronic administraion of nicotine on prolactin release in the rat: Inactivation of prolactin response by repeated injections of nicotine
77. Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat
78. Nicotinic binding in rat brain: Autoradiographic comparison of [3H]acetylcholine, [3H]nicotine and [125I]-alpha-bungarotoxin
79. Existence of different subtypes of nicotinic acetylcholine receptors in the rat habenulo-interpeduncular system
80. Alpha3beta4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons
81. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function
82. Nicotinic acetylcholine receptors on hippocampal neurons: Distribution on the neuronal surface and modulation of receptor activity
83. Interleukin-2 (Il-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response
84. The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals with nicotinic acetylcholine receptor-like immunoreactivity in the median eminence of the rat
85. Changes in blood and plasma serotonergic measurements in rats - Effect of nicotine and/or exposure to different stresses
86. Cholinergic influences on hypothalamic-pituitary-adrenocortical activity of stressed rats: An approach utilizing agonists antagonists
87. Corticosterone-attenutating and anxiolytic properties of mecamylamine in the rat
88. Cardiovascular responses to cigarette smoke exposure in restrained conscious rats
89. Central nicotinic receptor blockade inhibits emotionally conditioned pressor responses in rats
90. Selective dopamine antagonists reduce nicotine self-administration
91. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
92. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats
93. Nicotine activates and desensitizes midbrain dopamine neurons
94. Relationship between sleep and mood in patients with rapid-cycling bipolar disorder
95. Nicotine and nicotinic receptors in the circadian system
96. Developmental changes in nicotinic receptor mRNAs and responses to nicotine in the suprachiasmatic nucleus and other brain regions
97. Gene expression in the brain across the sleep-waking cycle
98. A cholinergic antagonist, mecamylamine, blocks the phase-shifting effects of light on the circadian rhythm of locomotor activity in the golden hamster
99. A cholinergic antagonist, mecamylamine, blocks light-induced fos immunoreactivity in specific regions of the hamster suprachiasmatic nucleus
100. Depressive symptoms and cigarette smoking predict development and persistence of sleep problems in US adolescents
101. Tobacco withdrawal signs and symptoms among women with and without a history of depression
102. Comorbid bipolar disorder in tourette syndrome responds to nicotinic receptor antagonist mecamylamine (Inversine®)
103. Neuronal nicotinic receptor inhibition for treating mood disorders: Preliminary controlled evidence with mecamylamine
104. Treatment of Tourette disorder with transdermal nicotine and haloperidol
105. Transdermal nicotine for tourette's syndrome
106. Treatment of Tourette's syndrome with mecamylamine
107. Mecamylamine: New therapeutic uses and toxicity/risk profile
108. A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects
109. Accumbal dopamine overflow after ethanol: Localization of the antagonizing effect of mecamylamine
110. Multi-center double blind placebo controlled study of mecamylamine monotherapy for Tourette's disorder
111. A randomized trial of nortriptyline for smoking cessation
112. Antidepressants for smoking cessation (Cochrane Review)
113. Mood, major depression, fluoxetine response in cigarette smokers
114. Individual variability in responses to nicotine
115. The treatment of bipolar depression
116. Bipolar depression: Pharmacotherapy and related therapeutic strategies
117. Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine
118. Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists
119. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
120. Central nicotinic receptors, neurotrophic factors and neuroprotection
121. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease
122. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice
123. Chronic nicotine exposure reduces N-methyl-D-aspartate receptor-mediated damage in the hippocampus without altering calcium accumulation or extrusion: Evidence of calbindin-D28K overexpression
124. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors
125. Histological and behavioral protection by (-)-nicotine against quinolinic acid-induced neurodegeneration in the hippocampus
126. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity
127. Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation
128. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity
129. Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells
130. Alpha7 receptor-selective agonists and modes of alpha7 receptor activation
131. Activation and inhibition of rat neuronal nicotinic receptors by ABT-418
132. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo
133. Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists
134. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes
135. Development of a novel class of subtype-selective nicotinic receptor antagonist: Pyridine-N-substituted nicotine analogs
136. Rapid relief of block by mecamylamine of neuronal nicotinic acetylcholine receptors of rat chromaffin cells in vitro: An electrophysiological and modeling study
137. Pharmacological distinctions between functional nicotinic acetylcholine receptors on the PC12 rat pheochromocytoma and the TE671 human medulloblastoma
138. Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line
139. Antidepressant-like effects of a sub-type selective neuronal nicotinic receptor ligand, TC-1707, in the Forced Swim Test